A phase II study of pemetrexed in children with recurrent malignancies (COG ADVL 0525).

Trial Profile

A phase II study of pemetrexed in children with recurrent malignancies (COG ADVL 0525).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Pemetrexed (Primary)
  • Indications Brain cancer; Ewing's sarcoma; Glioma; Medulloblastoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Solid tumours
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 03 Mar 2010 Actual number of patients (75) added as reported by ClinicalTrials.gov record.
    • 03 Mar 2010 Actual number of patients (75) added as reported by ClinicalTrials.gov record.
    • 03 Mar 2010 Actual end date (1 Feb 2010) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top